Though the first-line treatment for DME is overwhelmingly anti-VEGF drug therapy, there may be room for treatment with steroids, explains Anat Loewenstein, MD, MHA.
There is a subset of patients with persistent DME that forms the impetus for new treatment strategies. Pravin U. Dugel, MD, outlines a list of potential candidates that may lead this paradigm shift. Who are these patients?
Quantitative assessment of retinovascular features on ultra-widefield angiography showed significant improvements in leakage and ischemia following treatment with aflibercept in patients with DME and RVO. Justis P. Ehlers, MD, shares more.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
